Citius Pharmaceuticals
CTXR
8 hedge funds and large institutions have $962K invested in Citius Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 4 closing their positions.
122% more capital invested
Capital invested by funds: $434K → $962K (+$528K)
0.15% more ownership
Funds ownership: 0.06% → 0.21% (+0.15%)
27% less funds holding
Funds holding: 11 → 8 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$931K |
| 2 |
Renaissance Technologies
New York
|
+$24.4K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$22.6K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.85K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$924 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Miller Investment Management
West Conshohocken,
Pennsylvania
|
-$68K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$4.69K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $768K | +$931K | +27,200 | +1,164% |
|
|
2
Renaissance Technologies
New York
| $79K | +$24.4K | +712 | +31% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $56K | +$1.85K | +54 | +3% |
|
|
SM
4
Sabby Management
Miami Beach,
Florida
| $29K | +$22.6K | +659 | +142% |
|
5
Dimensional Fund Advisors
Austin,
Texas
| $14K | – | – | – |
|
|
RJA
6
Raymond James & Associates
St Petersburg,
Florida
| $12K | – | – | – |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $3K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $1K | +$924 | +27 | New |
|
|
MIM
9
Miller Investment Management
West Conshohocken,
Pennsylvania
| – | -$68K | -1,600 | Closed |
|
|
10
Bank of America
Charlotte,
North Carolina
| – | -$4.69K | -137 | Closed |
|
CTXR Hedge Fund Activity: Q4 2018 in Review
8 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q4 2018, worth a combined $962K — up 122% from $434K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CTXR and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 4 added.
The largest buyer was Armistice Capital, adding an estimated $931K. The largest seller was Miller Investment Management, exiting entirely with an estimated $68K sold.
- 8 institutional investors held Citius Pharmaceuticals (CTXR) as of Q4 2018, down from 11 in Q3 2018.
- Funds reported $962K of Citius Pharmaceuticals stock for Q4 2018, up 122% quarter-over-quarter.
- 1 fund opened new Citius Pharmaceuticals positions in Q4 2018 and 4 closed out, a net change of -3 holders.
- The largest Citius Pharmaceuticals buyer in Q4 2018 was Armistice Capital, an estimated $931K added.
- The largest Citius Pharmaceuticals seller in Q4 2018 was Miller Investment Management, an estimated $68K sold.
Based on aggregated 13F filings for Q4 2018.